Dr. Reddy’s Laboratories launches Somazina for stroke patients in India

16 May 2015 Evaluate

Dr. Reddy’s Laboratories has launched Somazina, the innovator brand of Citicoline in the Indian market. The company has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India. This is an important product in the management of stroke and has been used for the treatment of post-stroke patients around the world.

Somazina is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries. Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.



Dr. Reddys Lab Share Price

5730.85 -53.00 (-0.92%)
04-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1455.00
Dr. Reddys Lab 5730.85
Cipla 1459.75
Zydus Lifesciences 1007.20
Lupin 1564.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.